Mutations in PIK3CA p.E545K and amplification in ERBB2 were common in breast cancers, BRAF p.V600E in metastatic melanoma and IDH1 p.R132H in IDH-mutant gliomas (Fig. 1a). Here, ERBB2 is linked to metastatic melanoma.